

Freedom of Information Request – AN080422

Q1. In the last 3 months, how many patients have been initiated* on the following agents for treatment for melanoma?

- Nivolumab (monotherapy)
- Nivolumab AND Ipilimumab (combination)

***Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.**

Q2. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma?

- Nivolumab (monotherapy)
- Nivolumab + Ipilimumab
- Nivolumab + Cabozantinib
- Avelumab + Axitinib

***Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.**

Q3. In the past 3 months, how many patients have been initiated* on the following agents for treatment for Advanced/Metastatic Oesophageal Cancer:

- Nivolumab (monotherapy)
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)

***Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.**

None in answer to all of the questions as the Northern H&SC Trust do not treat the cancers named above.